Drugs that contain Telotristat Etiprate

1. Drug name - XERMELO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7709493 TERSERA 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
Dec, 2027

(5 years from now)

US7553840 TERSERA 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
Dec, 2027

(5 years from now)

US8193204 TERSERA Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use
Feb, 2031

(8 years from now)

CN101809018A TERSERA Solids Forms Of ( S) -Ethyl 2-Amin0-3- (4- (2 -Amino- 6- ( (R) -1- (4-Chl0R0-2- O-Methyl-Ih-Pyrazol- 1-Yl) Phenyl) -2, 2, 2-Trifluorethoxy) -Pyrimidin-4-Yl) Phenyl) Propanoate
Sep, 2028

(5 years from now)

CN101809018B TERSERA (S)--2-Amino--3-(4-(2-Amino--6-((R) -1-(4-Chloro--2-(3-Methyl--1H-Pyrazol--1-Yl) Phenyl) -2, 2, 2-Trifluoro-Ethyoxyl)-Pyrimidin--4-Yl) Phenyl) Ethyl Propionate In Solid Form And Methods Of Use Thereof
Sep, 2028

(5 years from now)

IN282661B TERSERA 4-Phenyl-6-(2,2,2- Trifluoro-1- Phenylethoxy) Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

IN200903374P4 TERSERA 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy) Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

IN281019B TERSERA Crystalline Forms Of Tryptophan Hydroxylase Inhibitor And Pharmceutically Acceptable Salts Thereof
Sep, 2028

(5 years from now)

IN201002222P1 TERSERA Solids Forms Of (S)-Ethyl 2-Amin0-3-(4-(2-Amino-6-(R)-1-(4-Chl0R0-2-0-Methyl-Ihpyrazol- 1-Yl) Phenyl)-2, 2, 2-Trifluorethoxy) -Pyrimidin-4-Yl) Phenyl) Propanoate
Sep, 2028

(5 years from now)

EP2589600A1 TERSERA 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

EP3176159B1 TERSERA 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

EP2589600B1 TERSERA 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

EP3176159A1 TERSERA 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

EP2091940B1 TERSERA 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

EP2091940A2 TERSERA 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

EP2091940B3 TERSERA 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

EP2203444B1 TERSERA Solids Forms Of ( S) -Ethyl 2-Amin0-3- (4- (2 -Amino- 6- ( (R) -1- (4-Chl0R0-2- O-Methyl-Ih-Pyrazol- 1-Yl) Phenyl) -2, 2, 2-Trifluorethoxy) -Pyrimidin-4-Yl) Phenyl) Propanoate
Sep, 2028

(5 years from now)

EP2203444A1 TERSERA Solids Forms Of ( S) -Ethyl 2-Amin0-3- (4- (2 -Amino- 6- ( (R) -1- (4-Chl0R0-2- O-Methyl-Ih-Pyrazol- 1-Yl) Phenyl) -2, 2, 2-Trifluorethoxy) -Pyrimidin-4-Yl) Phenyl) Propanoate
Sep, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7968559 TERSERA Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds Dec, 2027

(5 years from now)

US8653094 TERSERA Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use Dec, 2028

(6 years from now)

Treatment: The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 250MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.